Colin Foster
Chief Executive Officer at iSci Management LLC
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Jingjun Huang | M | - |
Ascendia Pharmaceuticals, Inc.
 Ascendia Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ascendia Pharmaceuticals LLC engages in the invention and development of specialty pharmaceutical products and novel formulation technologies. It offers rapid development and special development programs. The company was founded by Jingjun Huang in 2012 and is headquartered in North Brunswick, NJ. | 12 years |
| Robert Bloder | M | - |
Ascendia Pharmaceuticals, Inc.
Ascendia Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ascendia Pharmaceuticals LLC engages in the invention and development of specialty pharmaceutical products and novel formulation technologies. It offers rapid development and special development programs. The company was founded by Jingjun Huang in 2012 and is headquartered in North Brunswick, NJ. | - |
| J. Prichard | M | 75 |
University of Toronto
| 40 years |
| Mark F. Miller | M | - |
University of New Haven
| - |
| Heike Hausfeld | F | 58 | 30 years | |
| John C. Deacon | M | - |
Cytosolix, Inc.
 Cytosolix, Inc. Miscellaneous Commercial ServicesCommercial Services Cytosolix, Inc. is a company that provides products or services related to the field of life sciences or biotechnology. The company is based in Tolland, CT. Foster. The company was founded by Colin J. | - |
| Muhammad Asif | M | - |
Ascendia Pharmaceuticals, Inc.
Ascendia Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ascendia Pharmaceuticals LLC engages in the invention and development of specialty pharmaceutical products and novel formulation technologies. It offers rapid development and special development programs. The company was founded by Jingjun Huang in 2012 and is headquartered in North Brunswick, NJ. | - |
| Beverly Langevin | M | - |
Ascendia Pharmaceuticals, Inc.
Ascendia Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ascendia Pharmaceuticals LLC engages in the invention and development of specialty pharmaceutical products and novel formulation technologies. It offers rapid development and special development programs. The company was founded by Jingjun Huang in 2012 and is headquartered in North Brunswick, NJ. | 11 years |
| Michael Davis | M | - |
University of New Haven
| - |
| Michael Ambrose | M | 62 |
University of New Haven
| - |
| Steven Kaplan | M | 71 |
University of New Haven
| 20 years |
| Raphael Crawford | M | - |
University of New Haven
| - |
| M. Frederic Rieders | M | - |
University of New Haven
| - |
| Joshua H. Sandman | M | 81 |
University of New Haven
| - |
| Lap-Chee Tsui | M | 73 |
University of Toronto
| 41 years |
| Carlos S. Batista | M | 74 |
University of New Haven
| - |
| Shelley Stewart | F | 70 |
University of New Haven
| - |
| Theron Odlaug | M | 75 |
Ascendia Pharmaceuticals, Inc.
Ascendia Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ascendia Pharmaceuticals LLC engages in the invention and development of specialty pharmaceutical products and novel formulation technologies. It offers rapid development and special development programs. The company was founded by Jingjun Huang in 2012 and is headquartered in North Brunswick, NJ. | 3 years |
| Tak-Wah Mak | M | 77 |
University of Toronto
| 40 years |
| Paul Achleitner | M | 67 | 22 years | |
| Thomas Conforti | M | 65 |
Vista Life Innovations, Inc.
| 4 years |
| James Gale | M | 74 |
Ascendia Pharmaceuticals, Inc.
Ascendia Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ascendia Pharmaceuticals LLC engages in the invention and development of specialty pharmaceutical products and novel formulation technologies. It offers rapid development and special development programs. The company was founded by Jingjun Huang in 2012 and is headquartered in North Brunswick, NJ. | - |
| Robert Alvine | M | 85 |
University of New Haven
| - |
| Dolores Ennico | F | 71 |
University of New Haven
| 13 years |
| Andrew Avi Goldenberg | M | 80 |
University of Toronto
| 42 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Udi Gilboa | M | 57 |
Bioblast Pharma Ltd.
 Bioblast Pharma Ltd. BiotechnologyHealth Technology Bioblast Pharma Ltd. operates as a clinical development-stage biopharmaceutical company. It focuses on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic diseases. The company also focuses on diseases with severe and debilitating manifestations, where the unmet medical need is clear, the biological mechanism of action is understood, and for which there is no satisfactory treatment. Its product candidates include Protein Stabilizing, Read-through, and Mitochondrial Protein Replacement Platforms. The company was founded by Dalia Megiddo and Ehud Moshe Gilboa on January 22, 2012 and is headquartered in Tel Aviv, Israel. | 5 years |
| David I. Scheer | M | 71 |
Optherion, Inc.
 Optherion, Inc. Medical SpecialtiesHealth Technology Optherion, Inc. develops therapeutic products. It develops products to diagnose and treat dry and wet Age-related Macular Degeneration and other chronic diseases involving the alternative complement system. The company was founded by Gregory S. Hageman, David I. Scheer and Sandy Gordon in 2005 and is headquartered in New Haven, CT. | - |
| Kwok Cheung Chan | M | 62 |
University of Toronto
| 6 years |
| Johannes M. Dietsch | M | 62 | 16 years | |
| William Middleton | M | - |
University of Western Ontario
| 7 years |
| Brett Norris | M | - |
University of Western Ontario
University of Toronto
| 6 years |
| Ronald Daniels | M | 64 |
University of Toronto
| 8 years |
| Pamela Griffith-Jones | F | - |
University of Western Ontario
| 7 years |
| Jan-Anders Karlsson | M | 69 |
Bayer Pharmaceuticals Corp.
| - |
| Davin Andrew Gibbins | M | - |
University of Toronto
| 5 years |
| Gili Cohen | M | 57 |
Bioblast Pharma Ltd.
Bioblast Pharma Ltd. BiotechnologyHealth Technology Bioblast Pharma Ltd. operates as a clinical development-stage biopharmaceutical company. It focuses on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic diseases. The company also focuses on diseases with severe and debilitating manifestations, where the unmet medical need is clear, the biological mechanism of action is understood, and for which there is no satisfactory treatment. Its product candidates include Protein Stabilizing, Read-through, and Mitochondrial Protein Replacement Platforms. The company was founded by Dalia Megiddo and Ehud Moshe Gilboa on January 22, 2012 and is headquartered in Tel Aviv, Israel. | 3 years |
| Mark Eugene Hawman | M | - |
University of Western Ontario
| 4 years |
| Andrew Pyle | M | - |
University of Toronto
| 5 years |
| Brian Miron | M | - |
University of Toronto
| 5 years |
| Bernd Metzner | M | 53 | 4 years | |
| Mike Miller | M | - |
University of Western Ontario
University of Toronto
| 5 years |
| Gadi Mayman | M | - |
University of Western Ontario
University of Toronto
| 7 years |
| Flora Wood | F | - |
University of Toronto
| 5 years |
| Elizabeth M. Nash | F | - |
University of Toronto
| 5 years |
| Ulrich Hauck | M | 60 | 12 years | |
| John Meyer | M | - |
University of Western Ontario
| 5 years |
| Paul English | M | - |
University of Toronto
| - |
| Ira Kagan | M | 61 |
University of Toronto
| 7 years |
| Hamid Mumin | M | - |
University of Toronto
| 4 years |
| Eric H. Meerkamper | M | - |
University of Western Ontario
| 4 years |
| Hee Lum Chow | M | - |
University of Toronto
| 5 years |
| Kin Man Lam | M | 63 |
University of Toronto
| 6 years |
| Oren Elmaliah | M | 40 |
Bioblast Pharma Ltd.
Bioblast Pharma Ltd. BiotechnologyHealth Technology Bioblast Pharma Ltd. operates as a clinical development-stage biopharmaceutical company. It focuses on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic diseases. The company also focuses on diseases with severe and debilitating manifestations, where the unmet medical need is clear, the biological mechanism of action is understood, and for which there is no satisfactory treatment. Its product candidates include Protein Stabilizing, Read-through, and Mitochondrial Protein Replacement Platforms. The company was founded by Dalia Megiddo and Ehud Moshe Gilboa on January 22, 2012 and is headquartered in Tel Aviv, Israel. | - |
| Robert Friedman | M | 68 |
Bioblast Pharma Ltd.
Bioblast Pharma Ltd. BiotechnologyHealth Technology Bioblast Pharma Ltd. operates as a clinical development-stage biopharmaceutical company. It focuses on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic diseases. The company also focuses on diseases with severe and debilitating manifestations, where the unmet medical need is clear, the biological mechanism of action is understood, and for which there is no satisfactory treatment. Its product candidates include Protein Stabilizing, Read-through, and Mitochondrial Protein Replacement Platforms. The company was founded by Dalia Megiddo and Ehud Moshe Gilboa on January 22, 2012 and is headquartered in Tel Aviv, Israel. | 2 years |
| Sandy Der | M | - |
University of Toronto
| 13 years |
| Frank Morich | M | 69 | 20 years | |
| Gregory S. Hageman | M | - |
Optherion, Inc.
Optherion, Inc. Medical SpecialtiesHealth Technology Optherion, Inc. develops therapeutic products. It develops products to diagnose and treat dry and wet Age-related Macular Degeneration and other chronic diseases involving the alternative complement system. The company was founded by Gregory S. Hageman, David I. Scheer and Sandy Gordon in 2005 and is headquartered in New Haven, CT. | - |
| Jay G. Goldman | M | 61 |
University of Western Ontario
| 5 years |
| George Elston | M | 59 |
Optherion, Inc.
Optherion, Inc. Medical SpecialtiesHealth Technology Optherion, Inc. develops therapeutic products. It develops products to diagnose and treat dry and wet Age-related Macular Degeneration and other chronic diseases involving the alternative complement system. The company was founded by Gregory S. Hageman, David I. Scheer and Sandy Gordon in 2005 and is headquartered in New Haven, CT. | 2 years |
| Gail Mudie | F | - |
University of Toronto
| 6 years |
| Bill Maslechko | M | 63 |
University of Toronto
| 4 years |
| Stephanie B. Griffiths | F | - |
University of Toronto
| - |
| Thomas Dubin | M | 62 |
Bioblast Pharma Ltd.
Bioblast Pharma Ltd. BiotechnologyHealth Technology Bioblast Pharma Ltd. operates as a clinical development-stage biopharmaceutical company. It focuses on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic diseases. The company also focuses on diseases with severe and debilitating manifestations, where the unmet medical need is clear, the biological mechanism of action is understood, and for which there is no satisfactory treatment. Its product candidates include Protein Stabilizing, Read-through, and Mitochondrial Protein Replacement Platforms. The company was founded by Dalia Megiddo and Ehud Moshe Gilboa on January 22, 2012 and is headquartered in Tel Aviv, Israel. | 3 years |
| Samuil Umansky | M | - | 7 years | |
| Francis Shen | M | 65 |
University of Toronto
| 5 years |
| Jon A. Douglas | M | 61 |
University of Toronto
| 4 years |
| Jeffrey Harley Cole | M | - |
University of Toronto
| 7 years |
| Vikas Sinha | M | 60 |
Bayer Pharmaceuticals Corp.
| 11 years |
| Karl-Ludwig Kley | M | 73 | 16 years | |
| Michael Liik | M | 64 |
University of Toronto
| 6 years |
| Chaime Orlev | M | 53 |
Bioblast Pharma Ltd.
Bioblast Pharma Ltd. BiotechnologyHealth Technology Bioblast Pharma Ltd. operates as a clinical development-stage biopharmaceutical company. It focuses on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic diseases. The company also focuses on diseases with severe and debilitating manifestations, where the unmet medical need is clear, the biological mechanism of action is understood, and for which there is no satisfactory treatment. Its product candidates include Protein Stabilizing, Read-through, and Mitochondrial Protein Replacement Platforms. The company was founded by Dalia Megiddo and Ehud Moshe Gilboa on January 22, 2012 and is headquartered in Tel Aviv, Israel. | 1 years |
| Gerald D. Mintz | M | 71 |
University of Toronto
| 3 years |
| Michel Fattouche | M | 66 |
University of Toronto
| 5 years |
| Chung Wing Cheung | M | 66 |
University of Toronto
| 4 years |
| Mark di Vito | M | 58 |
University of Toronto
| 4 years |
| Simon Landy | M | 63 |
University of Toronto
| 1 years |
| Ching Leung Lo | M | 58 |
University of Toronto
| 4 years |
| KULDEEP NEOTE | M | - |
University of Toronto
| 7 years |
| Lusy Miranda | F | 67 |
University of Toronto
| 4 years |
| Sean Boyd | M | 65 |
University of Toronto
| 4 years |
| Alan Greenberg | M | - |
University of Toronto
| 4 years |
| John Davison | M | 65 |
University of Toronto
| 6 years |
| Kwok Loong Lo | M | 60 |
University of Toronto
| 4 years |
| Jonathan Go | M | 59 |
University of Toronto
| 2 years |
| William Leckie | M | - |
University of Toronto
| 4 years |
| Bruno M. Scherzinger | M | - |
University of Toronto
| 3 years |
| Stuart Berkowitz | M | - |
University of Toronto
| 3 years |
| David Kotler | M | 62 |
University of Toronto
| 4 years |
| Roger Daher | M | 58 |
University of Toronto
| 4 years |
| Anthony Cina | M | 60 |
University of Toronto
| 4 years |
| David Garofalo | M | 58 |
University of Toronto
| 14 years |
| James Penturn | M | - |
University of Toronto
| 4 years |
| Raymond Kruck | M | - |
University of Toronto
| 4 years |
| Neil Sheehy | M | - |
University of Toronto
| 4 years |
| Ray Verhoeff | M | - |
University of Toronto
| 4 years |
| Rosemary Zigrossi | F | - |
University of Toronto
| 4 years |
| Paul Petrashko | M | - |
University of Toronto
| 4 years |
| Randy Koroll | M | 59 |
University of Toronto
| 4 years |
| Leonard Makowka | M | 70 |
University of Toronto
| 3 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Canada | 61 | 61.62% |
| United States | 25 | 25.25% |
| Germany | 8 | 8.08% |
| Israel | 6 | 6.06% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Colin Foster
- Personal Network
